EDGAR Filing Documents for 0000950170-22-020973

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:

SEC Accession No. 0000950170-22-020973

Filing Date

2022-11-02

Accepted

2022-11-02 07:16:25

Documents

111

Period of Report

2022-09-30

Document Format Files

Seq	Description	Document	Type	Size
1	10-Q	hznp-20220930.htm iXBRL	10-Q	6221318
2	EX-31.1	hznp-ex31_1.htm	EX-31.1	13842
3	EX-31.2	hznp-ex31_2.htm	EX-31.2	13281
4	EX-32.1	hznp-ex32_1.htm	EX-32.1	11209
5	EX-32.2	hznp-ex32_2.htm	EX-32.2	11101
	Complete submission text file	0000950170-22-020973.txt		20978527

Data Files

Seq	Description	Document	Type	Size
6	XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT	hznp-20220930.xsd	EX-101.SCH	104735
7	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT	hznp-20220930_cal.xml	EX-101.CAL	94805
8	XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT	hznp-20220930_lab.xml	EX-101.LAB	764806
9	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT	hznp-20220930_pre.xml	EX-101.PRE	657861
10	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT	hznp-20220930_def.xml	EX-101.DEF	438207
105	EXTRACTED XBRL INSTANCE DOCUMENT	hznp-20220930_htm.xml	XML	4583174

Mailing Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4

Business Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100

Horizon Therapeutics Public Ltd Co (Filer) CIK: 0001492426 (see all company filings)